Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Ap, Jonville Béra"'
Autor:
E Autret, AP Jonville-Béra
Publikováno v:
Journal de Pédiatrie et de Puériculture. 10:150-152
La fievre est l'un des symptomes les plus frequents chez l'enfant. Elle merite d'etre traitee afin d'ameliorer le confort de l'enfant et de prevenir les convulsions. Si la necessite de traiter la fievre est admise, se pose le probleme de la strategie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1118ecb80e31a1cd07867ee7162d0636
https://doi.org/10.1016/s0987-7983(97)80112-0
https://doi.org/10.1016/s0987-7983(97)80112-0
Publikováno v:
Europe PubMed Central
Pharmacokinetic studies in neonates are essential because of maturational changes in physiological functions during this period. International harmonization conferences have established guidelines for such studies, including recommendations on age ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::cd818384cec600b1fb076405fe0ce6c4
http://europepmc.org/abstract/med/11878088
http://europepmc.org/abstract/med/11878088
Autor:
Crommelynck S; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France. Electronic address: samuel.crommelynck@ansm.sante.fr., Grandvuillemin A; Regional Pharmacovigilance Centre of Burgundy, University Hospital Dijon Bourgogne, 21000 Dijon, France., Ferard C; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France., Mounier C; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France., Gault N; French National Agency for Medicines and Health Products Safety, ANSM, General Direction for Operations, PRAC representative, 93200 Saint-Denis, France., Pierron E; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France., Jacquot B; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France., Vaillant T; French National Agency for Medicines and Health Products Safety, ANSM, General Direction for Operations, PRAC representative, 93200 Saint-Denis, France., Chatelet IPD; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Santé Publique France, Infectious Diseases, 94410 Saint-Maurice, France., Jacquet A; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France., Salvo F; Regional Pharmacovigilance Centre of Bordeaux, DROM, University Hospital of Bordeaux, 33000 Bordeaux, France; UMR 1219 Pharmacoepidemiology Team, Bordeaux Population Health Research Centre, Inserm, University of Bordeaux, 33000 Bordeaux, France., Alt M; Regional Pharmacovigilance Centre, University Hospital of Strasbourg, 67091 Strasbourg, France., Bagheri H; Department of Medical and ClinicalPharmacology, Centre of Pharmacovigilance, Pharmacoepidemiology and Informations on Medications, Inserm UMR 1027, University Hospital and Faculty of Medicine, 31000 Toulouse, France., Micallef J; Department of Clinical Pharmacology and Pharmacovigilance, Regional Pharmacovigilance Centre of Marseille, AP-HM, 13000 Marseille, France., Pariente A; Regional Pharmacovigilance Centre of Bordeaux, DROM, University Hospital of Bordeaux, 33000 Bordeaux, France., Gautier S; Departement of Clinical Pharmacology, University Hospital, Regional Pharmacovigilance Centre of Lille, 59000 Lille, France., Valnet-Rabier MB; Regional Pharmacovigilance Centre of Franche-Comté, University Hospital of Besançon, 25000 Besançon, France., Atzenhoffer M; University Hospital Department of Pharmacotoxicology, Regional Pharmacovigilance Centre, Civil Hospices of Lyon (HCL), 69003 Lyon, France., Lepelley M; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Regional Pharmacovigilance Centre, University Hospital of Grenoble-Alpes, 38000 Grenoble, France., Cottin J; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; University Hospital Department of Pharmacotoxicology, Regional Pharmacovigilance Centre, Civil Hospices of Lyon (HCL), 69003 Lyon, France., Lacroix I; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Department of Medical and ClinicalPharmacology, Centre of Pharmacovigilance, Pharmacoepidemiology and Informations on Medications, Inserm UMR 1027, University Hospital and Faculty of Medicine, 31000 Toulouse, France., Gras V; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Pharmacovigilance Centre, Department of Clinical Pharmacology, Amiens Picardie University Medical Centre, 80054 Amiens, France., Massy N; Regional Pharmacovigilance Centre, Clinical Pharmacology Department, Rouen University Hospital, 76031 Rouen, France., Dhanani A; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France., Vella P; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France., Shaim Y; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France., Baril L; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Santé Publique France, Infectious Diseases, 94410 Saint-Maurice, France., Jonville-Béra AP; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Departement of Pharmacosurveillance, University Hospital, Regional Pharmacovigilance Centre Val-de-Loire, 37000 Tours, France., Benkebil M; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France.
Publikováno v:
Therapie [Therapie] 2024 Nov 14. Date of Electronic Publication: 2024 Nov 14.
Autor:
Leducq S; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Tours, 37000 Tours, France. Electronic address: sophie.leducq@univ-tours.fr., Poizeau F; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Rennes, 35000 Rennes, France., Chaby G; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Amiens, 80000 Amiens, France; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France., Tannous J; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France., Ballanger-Desolneux F; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Bordeaux, 33000 Bordeaux, France., Baubion E; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU de Martinique, 97261 Fort de France, France., Bertolotti A; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; INSERM CIC1410, Service de maladies infectieuses-dermatologie, CHU de la Réunion, Site Sud, 97448 Saint-Pierre, France., Cogrel O; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Bordeaux, 33000 Bordeaux, France., Droitcourt C; Service de Dermatologie, CHU Rennes, 35000 Rennes, France; Univ Rennes, INSERM, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France., Garnier V; Pharmacie Garnier, 30840 Meynes, France., Gautier S; Pharmacologie Inserm U1171, Université de Lille, Centre régional de pharmacovigilance, CHU, 59000 Lille, France., Hefez L; Service de Dermatologie, Grand hôpital de l'Est Francilien, 77600 Jossigny, France., Hotz C; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Équipe transverse, Centre Hospitalier Jacques Puel, 12000 Rodez, France., Jonville-Béra AP; Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance, CHRU Tours, 37044 Tours, France., Jouan N; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Cabinet de Dermatologie, 29200 Brest, France., Mahé A; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CH Colmar, 68000 Colmar, France., Mahé E; Service de Dermatologie, CH Argenteuil, 78018 Argenteuil, France., Martinho G; Délégué Général, Fédération Française de la Peau, 75012 Paris, France., Micallef J; Service de Pharmacologie et pharmacovigilance, CHU Marseille, 13009 Marseille, France., Puszkarek T; Université de Bretagne Occidentale, 29200 Brest, France., Dupin N; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, Hôpital Cochin, AP-HP, 75014 Paris, France., Ly S; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Bordeaux, 33000 Bordeaux, France; Cabinet de Dermatologie, 33170 Gradignan, France., Beylot-Barry M; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Bordeaux, 33000 Bordeaux, France., Corgibet F; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Cabinet de Dermatologie, 21000 Dijon, France., Guillot B; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Université de Montpellier, 34000 Montpellier, France., Chosidow O; Centre de Preuves de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Groupe DEFI de la Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Consultation dermatoses faciales, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, 75013 Paris, France.
Publikováno v:
Annales de dermatologie et de venereologie [Ann Dermatol Venereol] 2024 Sep; Vol. 151 (3), pp. 103244. Date of Electronic Publication: 2024 Jun 07.
Autor:
Largeau B; CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France (B.L.)., Bergeron S; Université de Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille Neuroscience & Cognition, Unité Mixte de Recherche (UMR) 1172, équipe Troubles Cognitifs Dégénératifs et Vasculaires, Centre Hospitalier Universitaire (CHU) de Lille, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance, France (S.B., S.G., R.B.)., Auger F; Université de Lille, Centre National de la Recherche Scientifique (CNRS), INSERM, CHU Lille, Institut Pasteur de Lille, US 41, Unités Mixtes de Service 2014, Plateformes Lilloises en Biologie et Santé, Lille, France (F.A.)., Salmon Gandonnière C; CHRU de Tours, Service de Médecine Intensive Réanimation, réseau CRICS-TRIGGERSEP F-CRIN (Clinical Research in Intensive Care Sepsis Trial Group for Global Evaluation Research in Sepsis, a French Clinical Research Infrastructure Network) Research Network, Tours, France (C.S.G.)., Jonville-Béra AP; Université de Tours, Université de Nantes, INSERM, Methods in Patients-Centered Outcomes and Health Research (SPHERE), UMR 1246, CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France (A.-P.J.-B.)., Ehrmann S; Université de Tours, INSERM, Centre d'étude des Pathologies Respiratoires (CEPR), UMR 1100, CHRU de Tours, Service de Médecine Intensive Réanimation, CIC 1415, réseau CRICS-TRIGGERSEP F-CRIN Research Network, Tours, France (S.E.)., Gautier S; Université de Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille Neuroscience & Cognition, Unité Mixte de Recherche (UMR) 1172, équipe Troubles Cognitifs Dégénératifs et Vasculaires, Centre Hospitalier Universitaire (CHU) de Lille, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance, France (S.B., S.G., R.B.)., Bordet R; Université de Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille Neuroscience & Cognition, Unité Mixte de Recherche (UMR) 1172, équipe Troubles Cognitifs Dégénératifs et Vasculaires, Centre Hospitalier Universitaire (CHU) de Lille, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance, France (S.B., S.G., R.B.).
Publikováno v:
Stroke [Stroke] 2024 Feb; Vol. 55 (2), pp. 484-493. Date of Electronic Publication: 2023 Dec 21.
Autor:
Viguier T; Centre Hospitalier Universitaire (CHU) de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France., Agier MS; Centre Hospitalier Universitaire (CHU) de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France.; Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE)-UMR 1246, Tours, France., Jonville-Béra AP; Centre Hospitalier Universitaire (CHU) de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France.; Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE)-UMR 1246, Tours, France., Giraudeau B; Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE)-UMR 1246, Tours, France.; Centre Hospitalier Universitaire (CHU) de Tours, Centre d'investigation clinique-CIC INSERM 1415, Tours, France., Largeau B; Centre Hospitalier Universitaire (CHU) de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Feb; Vol. 90 (2), pp. 475-482. Date of Electronic Publication: 2023 Nov 02.
Autor:
Largeau B; Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance, Hôpital Bretonneau, CHU Tours, Tours, France., Thoreau B; Service de Médecine Interne-Immunologie Clinique, Hôpital Bretonneau, CHU Tours, Tours, France., Grangé S; Centre National de Référence pour les microangiopathies thrombotiques, Hôpital Saint-Antoine, Université de la Sorbonne, AP-HP, Paris, France.; Service de Néphrologie, Hôpital Bois-Guillaume, CHU Rouen, Rouen, France., Jonville-Béra AP; Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance, Hôpital Bretonneau, CHU Tours, Tours, France., Halimi JM; Centre National de Référence pour les microangiopathies thrombotiques, Hôpital Saint-Antoine, Université de la Sorbonne, AP-HP, Paris, France.; Service de Néphrologie, Hôpital Bretonneau, CHU Tours, Tours, France.
Publikováno v:
Journal of internal medicine [J Intern Med] 2023 Nov; Vol. 294 (5), pp. 665-678. Date of Electronic Publication: 2023 Aug 04.
Autor:
Wong So J; CHR d'Orléans, Service de Médecine Interne, Orléans, France.; CHR d'Orléans, Service de Médecine-Intensive Réanimation, Orléans, France., Bouibede F; CHR d'Orléans, Service de Médecine Interne, Orléans, France., Jonville-Béra AP; CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France., Maillot F; CHRU de Tours, Service de Médecine Interne et Immunologie Clinique, Tours, France., Barbier F; CHR d'Orléans, Service de Médecine-Intensive Réanimation, Orléans, France., Largeau B; CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France.
Publikováno v:
Journal of internal medicine [J Intern Med] 2023 Jul; Vol. 294 (1), pp. 58-68. Date of Electronic Publication: 2023 Apr 20.
Autor:
Lemoine L; Department of Internal Medicine and Clinical Immunology, CHRU Tours, 37044 Tours, France; University of Tours, 37000 Tours, France. Electronic address: lea.lemoine@univ-tours.fr., Agier MS; Regional Pharmacovigilance Center of Tours, Service de Pharmacosurveillance, CHRU, 37000 Tours, France; Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE) - UMR 1246, Tours 37044, France., Audemard-Verger A; Department of Internal Medicine and Clinical Immunology, CHRU Tours, 37044 Tours, France; University of Tours, 37000 Tours, France., Chouchana L; Regional Center of Pharmacovigilance, Department of Pharmacology, Cochin Hospital, AP-HP Centre - Université Paris Cité, 75000 Paris, France., Michot J; Regional Center of Pharmacovigilance, Saint Antoine Hospital (AP-HP), 75000 Paris, France., Jonville-Béra AP; Regional Pharmacovigilance Center of Tours, Service de Pharmacosurveillance, CHRU, 37000 Tours, France; Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE) - UMR 1246, Tours 37044, France., Maillot F; Department of Internal Medicine and Clinical Immunology, CHRU Tours, 37044 Tours, France; University of Tours, 37000 Tours, France; LabEx MabImprove, 37000 Tours, France.
Publikováno v:
Therapie [Therapie] 2023 Jul-Aug; Vol. 78 (4), pp. 409-417. Date of Electronic Publication: 2022 Oct 28.
Autor:
Largeau B; CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours 37044, France. Electronic address: berenger.largeau@etu.univ-tours.fr., Bordy R; Université de Tours, Transplantation, Immunologie et Inflammation (T2I) - EA4245, Tours 37044, France. Electronic address: romain.bordy@univ-tours.fr., Pasqualin C; Université de Tours, Transplantation, Immunologie et Inflammation (T2I) - EA4245, Tours 37044, France. Electronic address: come.pasqualin@univ-tours.fr., Bredeloux P; Université de Tours, Transplantation, Immunologie et Inflammation (T2I) - EA4245, Tours 37044, France. Electronic address: pierre.bredeloux@univ-tours.fr., Cracowski JL; CHU Grenoble Alpes, Centre Régional de Pharmacovigilance et d'Information sur les Médicaments, Grenoble 38000, France; University of Grenoble HP2, INSERM, Grenoble, 38000, France. Electronic address: jean-luc.cracowski@univ-grenoble-alpes.fr., Lengellé C; CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours 37044, France. Electronic address: c.lengelle@chu-tours.fr., Gras-Champel V; CHU d'Amiens, Service de Pharmacologie Clinique, Centre Régional de Pharmacovigilance d'Amiens, Amiens 80054, France. Electronic address: gras.valerie@chu-amiens.fr., Auffret M; Hospices Civils de Lyon, Service Hospitalo-Universitaire de Pharmacotoxicologie, Centre Régional de Pharmacovigilance, Lyon, France. Electronic address: marine.auffret@chu-lyon.fr., Maupoil V; Université de Tours, Transplantation, Immunologie et Inflammation (T2I) - EA4245, Tours 37044, France. Electronic address: veronique.maupoil@univ-tours.fr., Jonville-Béra AP; CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours 37044, France; Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE) - UMR 1246, Tours 37044, France. Electronic address: jonville-bera@chu-tours.fr.
Publikováno v:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 May; Vol. 149, pp. 112807. Date of Electronic Publication: 2022 Mar 15.